Truist Securities Maintains Hold on AnaptysBio, Raises Price Target to $50
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:ANAB) with a Hold and raises the price target from $36 to $50.
Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:ANAB) with a Hold and raises the price target from $36 to $50.